AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY19 results · Jul–Sep 2018
AstraZeneca Pharma India reported revenue from operations of ₹161.36 crore and net profit of ₹9.13 crore for Q2 FY19 (Jul–Sep 2018), on a standalone basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 161.36 | — | — | 161.44 | −0.0% |
| Other income | 3.35 | — | — | 3.42 | −2.0% |
| Total income | 164.72 | — | — | 164.86 | −0.1% |
| Profit before tax | 14.44 | — | — | 9.15 | +57.8% |
| Net profit for the period | 9.13 | — | — | 6.39 | +42.8% |
| EPS, basic (₹) | 3.65 | — | — | 2.56 | +42.9% |
| Net margin (%) | 5.7 | — | 4.0 |
Standalone
- Filed with BSE
- 23 Nov 2018, 14:17 IST
- Board meeting
- 13 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE